Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant ADT +/- Darolutamide Followed by Radical Prostatectomy for High-risk Prostate Cancer: a Randomized, Open Label Trial

NCT06575257 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT06575257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06575257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant ADT +/- Darolutamide Followed by Radical Prostatectomy for High-risk Prostate Cancer: a Randomized, Open Label Trial
Lead sponsor
Xijing Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2024
Completion date
May 31, 2029
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer